Wuhan Guanggu humanwell class 1.1 analgesic meisuoshuli obtained clinical approval
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Humanwell pharmaceutical announced in the evening of June 23 that the company's joint-stock subsidiary, Wuhan Optics Valley humanwell, had obtained the clinical approval documents for the 1.1-class chemical drug mesuosuli and two specifications of mesuosuli film coated tablets (50mg / 100mg), and could carry out phase I clinical trials At present, there are no other domestic enterprises applying for the product Meisuoshuli has anti-inflammatory, analgesic and antipyretic effects It is mainly used in the treatment of rheumatoid arthritis, osteoarthritis and other chronic arthritis It can also be used in surgery and acute post-traumatic pain and inflammation, otorhinopharyngeal inflammation, menstrual pain and other pain It can also be used in upper respiratory tract infection caused by fever and other diseases Compared with similar foreign drugs, it has It has the advantages of good curative effect and low side effects Humanwell pharmaceutical is mainly engaged in the pharmaceutical industry, and its market segments include anesthetics, analgesics, birth control drugs, blood products, Uyghur ethnic medicine, etc At present, humanwell holds 32.52% of the equity of Optics Valley humanwell, which is the largest shareholder of humanwell.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
